Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Selecting the right agonist depends on factors such as the patient's health profile and specific weight loss goals
[16] [17] Whether these risks apply to retatrutide specifically is not yet established, as the full long-term safety profile remains unknown pending Phase 3 data
In clinical trials, constipation was reported in approximately 12-17% of patients receiving tirzepatide for obesity (Zepbound) and 6-15% of patients with type 2 diabetes (Mounjaro), with higher rates at the 15 mg dose
These materials are provided for laboratory investigation and scientific experimentation and are not supplied for use in humans or animals
How soon will I see results
US$ 25.05
US$ 25.87
US$ 29.61
US$ 24.55
US$ 23.32
US$ 29.27
